Journal of Cancer Therapy
Vol.8 No.8(2017), Paper ID 78139, 9
pages
DOI:10.4236/jct.2017.88063
Cost-Minimization and Budget Impact Analysis of Rituximab SC VS Rituximab IV for Non-Hodgkin’s Lymphoma (NHLs) in Greece
Dionysis Kyriopoulos, Vasiliki Tsiantou, Labrini Papageorgiou, Fani Theodoropoulou, Kostas Athanasakis
Department of Health Economics, National School of Public Health, Athens, Greece
Department of Health Economics, National School of Public Health, Athens, Greece
Roche (Hellas), Athens, Greece
Roche (Hellas), Athens, Greece
Department of Health Economics, National School of Public Health, Athens, Greece
Copyright © 2017 Dionysis Kyriopoulos, Vasiliki Tsiantou, Labrini Papageorgiou, Fani Theodoropoulou, Kostas Athanasakis et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Kyriopoulos, D. , Tsiantou, V. , Papageorgiou, L. , Theodoropoulou, F. and Athanasakis, K. (2017) Cost-Minimization and Budget Impact Analysis of Rituximab SC VS Rituximab IV for Non-Hodgkin’s Lymphoma (NHLs) in Greece.
Journal of Cancer Therapy,
8, 726-734. doi:
10.4236/jct.2017.88063.